ASK1

GENFIT Updates 2024 Outlook Following Acceptance of Elafibranor Filings in Primary Biliary Cholangitis (PBC)

Retrieved on: 
Friday, December 8, 2023
Hepatic encephalopathy, Ipsen, AASLD, Cell death, Food, Itch, Priority review, Food and Drug Administration, PSC, IND, ACLF, Marketing, FDA, EMA, MAA, PDUFA, Permeability (electromagnetism), Liver, NDA, Inflammation, Primary sclerosing cholangitis, ALP, Capital market, Hyperammonemia, Patient, NTZ, Fibrosis, PBC, ASK1

Launches in the US and Europe will also make GENFIT eligible for royalty payments.

Key Points: 
  • Launches in the US and Europe will also make GENFIT eligible for royalty payments.
  • Revenues will fund the development of GENFIT’s pipeline, now mainly focused on Acute On-Chronic Liver Failure (ACLF) with 5 differentiated assets.
  • Acceptance of filings in the US and Europe have triggered the first milestone payment for GENFIT.
  • Ipsen also indicated that it is developing elafibranor in Primary Sclerosing Cholangitis (PSC) which could lead to further revenues for GENFIT under the licensing agreement.

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

Retrieved on: 
Thursday, November 16, 2023
Multiple organ dysfunction syndrome, Primary biliary cholangitis, Permeability (electromagnetism), Hepatic encephalopathy, PBC, AASLD, IND, Disease, Mortality, Cirrhosis, Elafibranor, UCSF, Patient, Heart, Liver, ASK1, Caregiver, NTZ, Chronic liver disease, Cell death, MBA, MD, University, Transplant, Doctor of Philosophy, Microbiota, Fibrosis, Ipsen, University of California, European Foundation, Human, Inflammation, Pharmaceutical industry, ACLF, Hyperammonemia, Boston, Euronext

GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.

Key Points: 
  • GENFIT is now mainly focused on the development of therapies for ACLF which is an area of very high unmet medical need.
  • ACLF is a potentially deadly, but reversible, condition in patients with chronic liver diseases, which is associated with multi-organ failure and high short-term mortality.
  • Pascal Prigent, CEO of GENFIT, commented: “During AASLD we were excited to further discuss our development strategy around our new pipeline focused on ACLF, where we believe multiple programs have the potential to transform the treatment paradigm for these patients.
  • As part of the “ACLF Day” event during AASLD, the critical need for treatment has been highlighted by leading experts in ACLF.

GENFIT Further Strengthens its ACLF Franchise with a Third Clinical-Stage Asset

Retrieved on: 
Wednesday, May 31, 2023
Anoxic waters, US Foods, Heart failure, Hepatology, IQVIA, Inflammation, NTZ, LPS, SOC, Liver, Fibrosis, Kidney, ROS, Orphan drug, Investigational New Drug, Acquisition, Patient, Standard of care, Apoptosis, Ascites, ASK1, Multi, FDA, Therapy, IND, Safety, Pharmaceutical industry, Vaccine, Dietary supplement, ACLF, Euronext

ACLF is a complex disorder that will likely require the combination of different approaches and with this acquisition, we continue to strengthen our leadership in this indication.

Key Points: 
  • ACLF is a complex disorder that will likely require the combination of different approaches and with this acquisition, we continue to strengthen our leadership in this indication.
  • We now have a unique portfolio of three differentiated clinical stage programs in ACLF.
  • It is planned that approximately 60 adult patients with ACLF grades 1 and 2 will be enrolled in this trial.
  • Data expected to be available in the first half of 2024 should support preparation of further testing of efficacy.

The Worldwide Non-Alcoholic Steatohepatitis Industry is Projected to Reach $15 Billion by 2027 - ResearchAndMarkets.com

Retrieved on: 
Monday, January 9, 2023
Health, Other Health, ASK1, Elafibranor, Fatty liver disease, FDA, Vitamin E, Diagnosis, Application, Prevalence, Distribution, Pharmacy, Liver, Pioglitazone, Investment, NASH, Obesity, Pharmaceutical industry

Elafibranor non-alcoholic steatohepatitis market is the fastest growing segment of global non-alcoholic steatohepatitis market in the forecasted period of 2023-2027 owing to positive impact of elafibranor in NASH treatment during clinical trials and drug's capability to reduce fat substance of liver, improving the conditions caused by NASH.

Key Points: 
  • Elafibranor non-alcoholic steatohepatitis market is the fastest growing segment of global non-alcoholic steatohepatitis market in the forecasted period of 2023-2027 owing to positive impact of elafibranor in NASH treatment during clinical trials and drug's capability to reduce fat substance of liver, improving the conditions caused by NASH.
  • By Application Type: The report provides the bifurcation of the market into two segments based on application type: treatment and diagnosis.
  • By Region: The report provides insight into the non-alcoholic steatohepatitis (NASH) market based on the regions namely North America, Europe, Asia Pacific, Middle East & Africa, and Latin America.
  • The Asia Pacific non-alcoholic steatohepatitis market is further divided into six regions on the basis of geographical operations, namely, China, India, Japan, Australia, South Korea and Rest of Asia Pacific, where China non-alcoholic steatohepatitis market held the largest share in Asia Pacific non-alcoholic steatohepatitis market.

Seal Rock Therapeutics to Present at Biotech Showcase 2023

Retrieved on: 
Thursday, January 5, 2023
Parkinson's disease, ASK1, Partnership, Institute of Liver and Biliary Sciences, Therapy, McDonnell Aircraft Corporation, NASH, Seal Rock, Disease, Alcoholic hepatitis, Biotechnology, Pharmaceutical industry

SEATTLE, Jan. 5, 2023 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced that Neil McDonnell, Chief Executive Officer, will present at Biotech Showcase 2023, taking place January 9-11, 2023 in San Francisco.

Key Points: 
  • SEATTLE, Jan. 5, 2023 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced that Neil McDonnell, Chief Executive Officer, will present at Biotech Showcase 2023, taking place January 9-11, 2023 in San Francisco.
  • McDonnell will review clinical and preclinical data for the company's lead clinical candidate, SRT-015, a second-generation apoptosis signal-regulating kinase (ASK1) inhibitor for treatment of alcoholic hepatitis, NASH, and other liver diseases.
  • Presentation details are as follows:
    Location/Track: Hilton San Francisco Union Square, Franciscan C (Ballroom Level)
    Seal Rock will also be conducting one-on-one investor meetings at the Biotech Showcase from January 9 to 11, 2023.
  • Biotech Showcase, produced by Demy-Colton and EBD Group, is an investor conference focused on driving advances in therapeutic development by providing a sophisticated networking platform for executives and investors that fosters investment and partnership opportunities.

U.S. Consumers Turning Back to Physical Stores This Shopping Season – Study by Aroscop

Retrieved on: 
Thursday, December 1, 2022
Technology, Department Stores, Marketing, Advertising, Communications, Software, Fashion, Retail, Data Management, Consumer electronics, Electronics, Behavior, ASK1, Habit, Clothing, Black Friday, Online shopping, Retail

Today, Adtech innovator Aroscop released insights from a recent pan-USA study revealing that consumers may have returned to physical stores this shopping season, starting with Black Friday last week.

Key Points: 
  • Today, Adtech innovator Aroscop released insights from a recent pan-USA study revealing that consumers may have returned to physical stores this shopping season, starting with Black Friday last week.
  • The study covered Consumer Electronics, Gifts & Toys, Apparel, and Home & Kitchen as the key shopping categories.
  • The study uncovered four significant aspects of shopping behavior:
    Where will they shop from - online vs. offline?
  • As American consumers eagerly return to physical stores after a long time, Aroscop gathered insights on key factors influencing their shopping behavior.

Seal Rock Therapeutics Announces Clinical and Preclinical Data on Differentiated ASK1 Inhibitor SRT-015 for Treatment of Alcoholic Hepatitis and Other Liver Diseases at The Liver Meeting® 2022

Retrieved on: 
Monday, November 7, 2022
ASK1, NASH, Non-alcoholic fatty liver disease, Therapy, Institute of Liver and Biliary Sciences, Plasma, AASLD, Seal Rock, Liver disease, Liver, Alcoholic hepatitis, Association, Patient, Drug discovery, American Association, Pharmaceutical industry

SEATTLE, Nov. 7, 2022 /PRNewswire/ -- Seal Rock Therapeutics, Inc., a clinical stage company developing first-in-class and best-in-class kinase inhibitors, today announced promising clinical and preclinical results for SRT-015, a second-generation apoptosis signal-regulating kinase (ASK1) inhibitor for treatment of alcoholic hepatitis and other liver diseases during an oral and poster presentation at The Liver Meeting® of the American Association for the Study of Liver Diseases (AASLD). The data demonstrate that SRT-015 is differentiated over first-generation ASK1 inhibitors and support future late-stage development of SRT-015.

Key Points: 
  • The data demonstrate that SRT-015 is differentiated over first-generation ASK1 inhibitors and support future late-stage development of SRT-015.
  • "Our presentations at The Liver Meeting support the promise of SRT-015 as a potential best-in-class second generation ASK1 inhibitor.
  • Our early clinical data are encouraging and support further advanced development efforts," said Neil McDonnell, Chief Executive Officer of Seal Rock Therapeutics.
  • SRT-015 is the next generation inhibitor of ASK1, developed internally by Seal Rock Therapeutics with the goal of overcoming liabilities that limited the clinical efficacy of selonsertib, the first ASK1 inhibitor to reach clinical development.

Seal Rock Therapeutics Announces Upcoming Presentations at AASLD's The Liver Meeting® 2020

Retrieved on: 
Monday, November 2, 2020
ASK1, Apoptosis, Programmed cell death

"Our presence at The Liver Meeting reflects the promising data we have compiled on SRT-015.

Key Points: 
  • "Our presence at The Liver Meeting reflects the promising data we have compiled on SRT-015.
  • Our data provide potential explanations for these failures and suggest that ASK1 inhibition remains an important therapeutic strategy for inflammatory and fibrotic diseases," said Neil McDonnell, Chief Executive Officer of Seal Rock Therapeutics.
  • Seal Rock Therapeutics is a privately held, preclinical stage company based in Seattle focused on developing first-in or best-in-class treatments for severe liver diseases with limited or no available therapies.
  • Seal Rock is led by an experienced management team with a track record of successful drug discovery, development and commercialization.

Aclaris Therapeutics Announces Positive Results From Phase 1 Single and Multiple Ascending Dose Trial of ATI-450, an Investigational Oral MK2 Inhibitor

Retrieved on: 
Thursday, January 9, 2020
Enzymes, Protein kinases, Mitogen-activated protein kinase, p38 mitogen-activated protein kinases, Protein kinase, Fostamatinib, ASK1

The trial consisted of three parts:

Key Points: 
  • The trial consisted of three parts:
    Single Ascending Dose (SAD) plus food effect (n=32, 8 subjects per dose cohort - 2 placebo, 6 active).
  • Multiple Ascending Dose (MAD) (n=30, 10 subjects per dose cohort - 2 placebo, 8 active).
  • Aclaris intends to initiate the first Phase 2 clinical trial in subjects with rheumatoid arthritis in the first half of 2020.
  • ATI-450 is an investigational oral small molecule inhibitor of the p38 mitogen-activated protein kinase-activated protein kinase 2 (MK2) inflammatory signaling pathway.